Soluble Suppression of Tumorigenicity 2 Associated with Contrast-induced Acute Kidney Injury in Patients with STEMI

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2024 Sep 12

PMID 39264493

Authors

Ziyun Luo

Yong Li

Minjuan Xie

Song Yi

Shizhang Xu

Jun Luo

Affiliations

Soon will be listed here.

Abstract

Background: Contrast-induced acute kidney injury (CI-AKI) is a common complication after percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI). Soluble suppression of tumorigenicity 2 (sST2) is associated with AKI. However, the relationship between sST2 and CI-AKI is unclear. This study aimed to investigate the relationship between sST2 and CI-AKI in patients with STEMI.

Methods: This was a single-center retrospective observational study. Patients diagnosed with STEMI in the Yichun People's Hospital from February 2020 to May 2024 were continuously included. CI-AKI was defined as an increase in serum creatinine of at least 50% or 0.3 mg/dL from baseline within 48-72 h after contrast exposure.

Results: The incidence of CI-AKI after PCI was 12.4% (98/791). Univariate analysis showed that age, fasting plasma glucose, diabetes mellitus, Killip class, left ventricular ejection fraction, estimated glomerular filtration rate, high sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, and sST2 were associated with CI-AKI. The above factors were included in a multivariate analysis, which showed that sST2 was an independent factor for CI-AKI after PCI. The restricted cubic splines showed a nonlinear dose-response relationship between sST2 and CI-AKI (P < 0.001). The integration of the sST2 could significantly improve the ability of the model to identify CI-AKI (NRI 0.681, 95% CI 0.474-0.887; IDI 0.063, 95% CI 0.038-0.099).

Conclusion: Elevated sST2 is an independent risk factor for CI-AKI after PCI in patients with STEMI. Integration of sST2 can significantly improve the risk model for CI-AKI.

Citing Articles

Associations between serum 25-hydroxyvitamin D and prognosis of chronic kidney disease: a prospective cohort study.

Mai Y, Yi Y, Wen Y, Huang P, Wang Y, Wang Z Int Urol Nephrol. 2024; 56(10):3323-3334.

PMID: 38767811 DOI: 10.1007/s11255-024-04083-9.

References

Solomon R, Dauerman H . Contrast-induced acute kidney injury. Circulation. 2010; 122(23):2451-5. DOI: 10.1161/CIRCULATIONAHA.110.953851. View

Ramachandran P, Jayakumar D . Contrast-induced Acute Kidney Injury. Indian J Crit Care Med. 2020; 24(Suppl 3):S122-S125. PMC: 7347061. DOI: 10.5005/jp-journals-10071-23379. View

McCullough P . Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008; 51(15):1419-28. DOI: 10.1016/j.jacc.2007.12.035. View

Abe D, Sato A, Hoshi T, Kakefuda Y, Watabe H, Ojima E . Clinical predictors of contrast-induced acute kidney injury in patients undergoing emergency versus elective percutaneous coronary intervention. Circ J. 2013; 78(1):85-91. DOI: 10.1253/circj.cj-13-0574. View

Kooiman J, Seth M, Nallamothu B, Heung M, Humes D, Gurm H . Association between acute kidney injury and in-hospital mortality in patients undergoing percutaneous coronary interventions. Circ Cardiovasc Interv. 2015; 8(6):e002212. DOI: 10.1161/CIRCINTERVENTIONS.114.002212. View

Rear R, Bell R, Hausenloy D . Contrast-induced nephropathy following angiography and cardiac interventions. Heart. 2016; 102(8):638-48. PMC: 4819627. DOI: 10.1136/heartjnl-2014-306962. View

Naidu S, Aronow H, Box L, Duffy P, Kolansky D, Kupfer J . SCAI expert consensus statement: 2016 best practices in the cardiac catheterization laboratory: (Endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista; Affirmation of value by the Canadian.... Catheter Cardiovasc Interv. 2016; 88(3):407-23. DOI: 10.1002/ccd.26551. View

Mehran R, Dangas G, Weisbord S . Contrast-Associated Acute Kidney Injury. N Engl J Med. 2019; 380(22):2146-2155. DOI: 10.1056/NEJMra1805256. View

Hossain M, Costanzo E, Cosentino J, Patel C, Qaisar H, Singh V . Contrast-induced nephropathy: Pathophysiology, risk factors, and prevention. Saudi J Kidney Dis Transpl. 2018; 29(1):1-9. DOI: 10.4103/1319-2442.225199. View

10.

Griesenauer B, Paczesny S . The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front Immunol. 2017; 8:475. PMC: 5402045. DOI: 10.3389/fimmu.2017.00475. View

11.

Yancy C, Jessup M, Bozkurt B, Butler J, Casey Jr D, Drazner M . 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62(16):e147-239. DOI: 10.1016/j.jacc.2013.05.019. View

12.

Moore S, Januzzi Jr J . Found in translation soluble ST2 and heart disease. J Am Coll Cardiol. 2010; 55(3):251-3. DOI: 10.1016/j.jacc.2009.08.049. View

13.

Dieplinger B, Januzzi Jr J, Steinmair M, Gabriel C, Poelz W, Haltmayer M . Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay. Clin Chim Acta. 2009; 409(1-2):33-40. DOI: 10.1016/j.cca.2009.08.010. View

14.

Lobdell K, Parker D, Likosky D, Rezaee M, Wyler von Ballmoos M, Alam S . Preoperative serum ST2 level predicts acute kidney injury after adult cardiac surgery. J Thorac Cardiovasc Surg. 2018; 156(3):1114-1123.e2. PMC: 6098731. DOI: 10.1016/j.jtcvs.2018.03.149. View

15.

Tung Y, Chang C, Chen Y, Chu P . Combined biomarker analysis for risk of acute kidney injury in patients with ST-segment elevation myocardial infarction. PLoS One. 2015; 10(4):e0125282. PMC: 4390355. DOI: 10.1371/journal.pone.0125282. View

16.

Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European.... Eur Heart J. 2017; 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. View

17.

van der Molen A, Reimer P, Dekkers I, Bongartz G, Bellin M, Bertolotto M . Post-contrast acute kidney injury - Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors : Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018; 28(7):2845-2855. PMC: 5986826. DOI: 10.1007/s00330-017-5246-5. View

18.

Silver S, Shah P, Chertow G, Harel S, Wald R, Harel Z . Risk prediction models for contrast induced nephropathy: systematic review. BMJ. 2015; 351:h4395. PMC: 4784870. DOI: 10.1136/bmj.h4395. View

19.

Bagci A, Aksoy F, Bas H . Systemic Immune-Inflammation Index May Predict the Development of Contrast-Induced Nephropathy in Patients With ST-Segment Elevation Myocardial Infarction. Angiology. 2021; 73(3):218-224. DOI: 10.1177/00033197211030053. View

20.

Kang J, Kim S, Yang S, Kim Y, Do Y, Park K . Clinical Characteristics and Management of Peripancreatic Arterial Aneurysms: A 20-year Experience. Angiology. 2023; :33197231225281. DOI: 10.1177/00033197231225281. View